Literature DB >> 14999365

The medical management of migraine.

Marcelo E Bigal1, Richard B Lipton, Abouch V Krymchantowski.   

Abstract

Migraine is a common, chronic neurologic disorder that affects 11% of the adult population in Western countries. In this article, we review the current approaches to the pharmacologic treatment of migraine. Once migraine is diagnosed, and illness severity has been assessed, clinicians and patients should work together to develop a treatment plan based on the patient needs and preferences. The goals of the treatment plan usually include reducing attack frequency, intensity, and duration; minimizing headache-related disability; improving health-related quality of life; and avoiding headache escalation and medication misuse. Medical treatments for migraine can be divided into preventive drugs, which are taken on a daily basis regardless of whether headache is present, and acute drugs taken to treat individual attacks as they arise. Acute treatments are further divided into nonspecific and migraine-specific treatments. The US Headache Consortium Guidelines recommend stratified care based on the level of disability to help physicians individualize treatment. Simple analgesics are appropriate as first-line acute treatments for less disabled patients; if simple analgesics are unsuccessful, treatment is escalated. For those with high disability levels, migraine-specific acute therapies, such as the triptans, are recommended as the initial treatment, with preventive drugs in selected patients. A variety of behavioral interventions are helpful. The clinicians have in their armamentariums an ever-expanding variety of medications. With experience, clinicians can match individual patient needs with the specific characteristics of a drug to optimize therapeutic benefit.

Entities:  

Mesh:

Year:  2004        PMID: 14999365     DOI: 10.1097/00045391-200403000-00008

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  8 in total

1.  A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients.

Authors:  Elham Bidabadi; Mehryar Mashouf
Journal:  Paediatr Drugs       Date:  2010-08-01       Impact factor: 3.022

Review 2.  Chronic disorders with episodic manifestations: focus on epilepsy and migraine.

Authors:  Sheryl R Haut; Marcelo E Bigal; Richard B Lipton
Journal:  Lancet Neurol       Date:  2006-02       Impact factor: 44.182

Review 3.  Emerging drugs for migraine prophylaxis and treatment.

Authors:  Marcelo E Bigal; Abouch V Krymchantowski
Journal:  MedGenMed       Date:  2006-05-04

4.  Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting.

Authors:  Abouch Krymchantowski; Cláudia Tavares
Journal:  MedGenMed       Date:  2004-07-14

5.  Health care utilization and changes in health status over time for migraineurs.

Authors:  Anderson Chuck; Philip Jacobs; Arto Ohinmaa; Donald Schopflocher; Saifudin Rashiq; Racquel Feroe
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

6.  Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity.

Authors:  Kathryn E Smith; J Graham Thomas; Kristine J Steffen; Richard B Lipton; Samantha G Farris; Jelena M Pavlovic; Dale S Bond
Journal:  Transl Behav Med       Date:  2021-08-13       Impact factor: 3.046

7.  Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update.

Authors:  Sergio Carmona; Osvaldo Bruera
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

Review 8.  A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.

Authors:  Linda Harris; Gilbert L'Italien; Thomas O'Connell; Zacharia Hasan; Susan Hutchinson; Sylvia Lucas
Journal:  Adv Ther       Date:  2021-05-31       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.